Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Nasus Pharma Ltd files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2023
FY2025
FY2025
Revenue
1,235
Research and development
0.57
0.34
2.24
General and administrative
0.58
0.74
2.67
Operating expenses
1.15
1.08
4.9
Operating income
-1.15
-1.08
-4.9
Interest expense
0.05
0.03
-0.08
Income from continuing operations
-1.01
-1.55
-5.81
Net income
-1.05
-1.53
-5.86
EPS, basic
-0.15
-0.22
-0.72
EPS, diluted
-0.20
-0.22
-0.72
Shares, basic (weighted)
6.89
7.03
8.01
Shares, diluted (weighted)
7.06
7.03
8.01
Balance sheet
FY2023
FY2025
FY2025
Cash and equivalents
0.19
0.28
1.24
Other current assets
0.03
0.19
Total current assets
0.46
4.86
Property, plant and equipment
0.01
Lease right-of-use assets
0.14
Total assets
0.72
5
Accounts payable
0.65
0.83
Accrued liabilities
0.84
0.55
Total current liabilities
3.93
2.16
Lease liabilities
0.07
Total liabilities
3.93
2.24
Paid-in capital
9.43
21.3
Retained earnings
-12.7
-18.5
Shareholders' equity
-3.8
-3.21
2.77
Total equity
-3.8
-3.21
2.77
Total liabilities and equity
0.72
5
Shares outstanding
7.36
9.02
Cash flow statement
FY2023
FY2025
FY2025
Net income
-1.05
-1.53
-5.86
Stock-based compensation
0.04
0.01
0.45
Change in payables
-0.12
-0.01
0.15
Cash from operations
-1.03
-0.67
-4.92
Capital expenditures
-0.01
Cash from investing
-3.01
Stock issued
8.49
Cash from financing
1.06
0.77
8.92
Net change in cash
0.04
0.1
0.98
Free cash flow
-4.93
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $3.48 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-0.4%
Operating income / revenue.
Net margin
-0.5%
Net income / revenue.
FCF margin
-0.4%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-0.4%
Cash from operations / revenue.
Return on assets (ROA)
-204.7%
Net income / average total assets.
R&D / revenue
0.2%
Research and development expense / revenue.
Stock-based pay / revenue
0.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.0%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Total assets growth, 1y
597.9%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
14.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.24x
Current assets / current liabilities.
Quick ratio
0.57x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.57x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.72
Net income per basic share, as reported (split-adjusted).
Revenue per share
$154.18
Revenue / diluted weighted shares.
FCF per share
-$0.62
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.61
Cash from operations / diluted weighted shares.
Book value per share
$0.31
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.03x
Market cap / revenue.
P/B
14.7x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
14.7x
Market cap / tangible book value, when positive.
EV/Sales
0.03x
Enterprise value / revenue.
FCF yield
-12.1%
Free cash flow / market cap.
Earnings yield
-14.4%
Net income / market cap (the inverse of P/E).
What was Nasus Pharma Ltd's revenue in fiscal 2025?
Nasus Pharma Ltd reported revenue of $1.24B for fiscal 2025.
Was Nasus Pharma Ltd profitable in fiscal 2025?
No. It reported a net loss of $5.9M.
How much free cash flow did Nasus Pharma Ltd generate in fiscal 2025?
Cash from operations of $4.9M minus capital expenditures of $14.0K left free cash flow of -$4.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.